المؤلفون: Nasser AM; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Melamed L; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Wetzel EA; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Chang JC; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Nagashima H; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Kobe University Graduate School of Medicine, Kobe, Japan., Kitagawa Y; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Muzyka L; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Wakimoto H; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Cahill DP; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Miller JJ; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jul 15; Vol. 30 (14), pp. 2996-3005.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Cyclin-Dependent Kinase 4*/genetics , Cyclin-Dependent Kinase 6*/antagonists & inhibitors , Cyclin-Dependent Kinase 6*/genetics , Glioma*/genetics , Glioma*/drug therapy , Glioma*/pathology , Cyclin-Dependent Kinase Inhibitor p16*/genetics , Isocitrate Dehydrogenase*/genetics , Isocitrate Dehydrogenase*/antagonists & inhibitors , Xenograft Model Antitumor Assays* , Benzimidazoles*/pharmacology , Cyclin-Dependent Kinase Inhibitor p15*/genetics , Aminopyridines*/pharmacology , Mutation* , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/therapeutic use , Piperazines*/pharmacology , Piperazines*/therapeutic use , Cell Proliferation*/drug effects , Pyridines*/pharmacology , Pyridines*/therapeutic use, Humans ; Animals ; Mice ; Cell Line, Tumor ; Gene Deletion ; Brain Neoplasms/genetics ; Brain Neoplasms/drug therapy ; Brain Neoplasms/pathology ; Homozygote

المؤلفون: Hou H; Department of Infectious Diseases, Xi'an Eighth's Hospital, Xi'an, Shaanxi, People's Republic of China., Ba H, Jin X, Luo P, Zhang Y, Li J, Jin J

المصدر: Medicine [Medicine (Baltimore)] 2024 Jul 05; Vol. 103 (27), pp. e38558.

نوع المنشور: Journal Article; Observational Study

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE

مواضيع طبية MeSH: Pyridones*/administration & dosage , Pyridones*/therapeutic use , Pyridones*/adverse effects , Lamivudine*/therapeutic use , Lamivudine*/administration & dosage , Lamivudine*/adverse effects , Heterocyclic Compounds, 3-Ring*/therapeutic use , Heterocyclic Compounds, 3-Ring*/adverse effects , Heterocyclic Compounds, 3-Ring*/administration & dosage , Oxazines* , HIV Infections*/drug therapy , HIV Infections*/complications , Piperazines*/therapeutic use , Piperazines*/administration & dosage , Piperazines*/adverse effects , Tuberculosis*/drug therapy , Tuberculosis*/complications , Drug Therapy, Combination* , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/adverse effects , Anti-HIV Agents*/administration & dosage, Humans ; Female ; Male ; Retrospective Studies ; Adult ; China ; Middle Aged ; Viral Load/drug effects ; Coinfection/drug therapy ; Treatment Outcome ; CD4 Lymphocyte Count

المؤلفون: Glade Bender JL; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Pinkney K; Department of Hematology-Oncology, Memorial Regional Hospital/Joe Dimaggio Children's Hospital, Hollywood, FL, United States., Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Roy-Chowdhuri S; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Coffey BD; Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Reid JM; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States., Piao J; Department of Biostatistics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States., Saguilig L; Children's Oncology Group Statistical Center, Monrovia, CA, United States., Alonzo TA; Department of Biostatistics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States., Berg SL; Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, United States., Ramirez NC; Biopathology Center, Nationwide Children's Hospital, Columbus, OH, United States., Fox E; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, United States., Weigel BJ; Department of Pediatrics, Hem/Onc/BMT, University of Minnesota Medical Center, Pediatric Hematology Oncology, Minneapolis, MN, United States., Hawkins DS; Department of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States., Mooney MM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD, United States., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD, United States., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States., Janeway KA; Department of Pediatrics, Dana Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, United States., Seibel NL; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD, United States., Parsons DW; Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, United States.

المصدر: The oncologist [Oncologist] 2024 Jul 05; Vol. 29 (7), pp. 638-e952.

نوع المنشور: Clinical Trial; Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: DNA Repair*/drug effects , DNA Repair*/genetics , Neoplasms*/drug therapy , Neoplasms*/genetics , Phthalazines*/therapeutic use , Phthalazines*/adverse effects , Phthalazines*/administration & dosage , Piperazines*/therapeutic use , Piperazines*/administration & dosage , Piperazines*/adverse effects, Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Young Adult ; Ataxia Telangiectasia Mutated Proteins/genetics ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; DNA Damage/drug effects ; DNA-Binding Proteins/genetics ; Germ-Line Mutation ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects

المؤلفون: Falasca K; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy. k.falasca@unich.it., Ucciferri C; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Di Gasbarro A; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Borrelli P; Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, University 'G. D'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Di Nicola M; Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, University 'G. D'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Frisenda C; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Costantini E; Department of Innovative Technologies in Medicine and Dentistry, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Aielli L; Department of Innovative Technologies in Medicine and Dentistry, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Reale M; Department of Innovative Technologies in Medicine and Dentistry, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy., Vecchiet J; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio', Via dei Vestini, Chieti, 66100, Italy.

المصدر: BMC infectious diseases [BMC Infect Dis] 2024 Jul 03; Vol. 24 (1), pp. 665. Date of Electronic Publication: 2024 Jul 03.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: HIV Infections*/drug therapy , Cytokines*/blood , Heterocyclic Compounds, 3-Ring*/therapeutic use , Heterocyclic Compounds, 3-Ring*/adverse effects , Heterocyclic Compounds, 3-Ring*/administration & dosage , Oxazines*/therapeutic use , Piperazines*/therapeutic use , Piperazines*/administration & dosage , Pyridones*/therapeutic use , Pyridones*/administration & dosage, Humans ; Male ; Female ; Adult ; Middle Aged ; Viral Load/drug effects ; Drug Therapy, Combination ; Anti-HIV Agents/therapeutic use ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; CD4 Lymphocyte Count

المؤلفون: Jing L; Department of Comprehensive Surgery, Zhengzhou People's Hospital, Zhengzhou, P. R. China., Liu C; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.; Henan Key Laboratory of Precision Clinical Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.

المصدر: Chemical biology & drug design [Chem Biol Drug Des] 2024 Jul; Vol. 104 (1), pp. e14584.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101262549 Publication Model: Print Cited Medium: Internet ISSN: 1747-0285 (Electronic) Linking ISSN: 17470277 NLM ISO Abbreviation: Chem Biol Drug Des Subsets: MEDLINE

مواضيع طبية MeSH: TRPV Cation Channels*/antagonists & inhibitors , TRPV Cation Channels*/metabolism , Piperazines*/chemistry , Piperazines*/pharmacology , Piperazines*/chemical synthesis , Analgesics*/pharmacology , Analgesics*/chemistry , Analgesics*/chemical synthesis, Animals ; Mice ; Humans ; Pain/drug therapy ; Structure-Activity Relationship ; Male ; HEK293 Cells ; Rats

المؤلفون: Keskinkilic M; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye., Semiz HS; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye., Yavuzsen T; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye., Karaoglu A; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye.

المصدر: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP [J Coll Physicians Surg Pak] 2024 Jul; Vol. 34 (7), pp. 851-853.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: College of Physicians and Surgeons Pakistan Country of Publication: Pakistan NLM ID: 9606447 Publication Model: Print Cited Medium: Internet ISSN: 1681-7168 (Electronic) Linking ISSN: 1022386X NLM ISO Abbreviation: J Coll Physicians Surg Pak Subsets: MEDLINE

مواضيع طبية MeSH: Purines*/adverse effects , Purines*/administration & dosage , Purines*/therapeutic use , Creatinine*/blood , Piperazines*/adverse effects , Piperazines*/administration & dosage , Piperazines*/therapeutic use , Aminopyridines*/adverse effects , Aminopyridines*/administration & dosage , Aminopyridines*/therapeutic use , Pyridines*/adverse effects , Pyridines*/administration & dosage , Cyclin-Dependent Kinase 4*/antagonists & inhibitors, Humans ; Female ; Middle Aged ; Aged ; Breast Neoplasms/drug therapy ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Adult ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/administration & dosage ; Male

المؤلفون: Yoshinami T; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan., Nagai SE; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan., Hattori M; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan., Okamura T; Department of Breast Oncology, Tokai University School of Medicine, Kanagawa, Japan., Watanabe K; Department of Breast Surgery, National Hospital Organization, Hokkaido Cancer Center, Hokkaido, Japan., Nakayama T; Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan., Masuda H; Department of Breast Surgical Oncology, School of Medicine, Showa University, Tokyo, Japan., Tsuneizumi M; Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan., Takabatake D; Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan., Harao M; Department of Breast Oncology, Jichi Medical University, Shimotsuke, Japan., Yoshino H; Breast and Endocrinological Surgery, Ishikawa Prefectural Central Hospital, Kanazawa, Japan., Mori N; Department of Breast Surgery, Seirei Hamamatsu General Hospital, Shizuoka, Japan., Yasojima H; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Oshiro C; Department of Breast Surgery, Kaizuka City Hospital, Kaizuka, Japan., Iwase M; Department of Breast and Endocrine Surgery, Nagoya University Hosipital, Nagoya, Japan., Yamaguchi M; Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, Japan., Sangai T; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Kanagawa, Japan., Kosaka N; Oncology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan., Tajima K; Oncology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan., Masuda N; Department of Breast and Endocrine Surgery, Nagoya University Hosipital, Nagoya, Japan. nmasuda@alpha.ocn.ne.jp.; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. nmasuda@alpha.ocn.ne.jp.

المصدر: Breast cancer (Tokyo, Japan) [Breast Cancer] 2024 Jul; Vol. 31 (4), pp. 621-632. Date of Electronic Publication: 2024 Apr 20.

نوع المنشور: Journal Article; Observational Study; Multicenter Study

بيانات الدورية: Publisher: Maruzen Co Country of Publication: Japan NLM ID: 100888201 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-4233 (Electronic) Linking ISSN: 13406868 NLM ISO Abbreviation: Breast Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Piperazines*/administration & dosage , Piperazines*/therapeutic use , Breast Neoplasms*/drug therapy , Breast Neoplasms*/mortality , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Pyridines*/administration & dosage , Pyridines*/therapeutic use , Receptor, ErbB-2*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Receptors, Progesterone*/metabolism , Progression-Free Survival* , Receptors, Estrogen*/metabolism, Humans ; Female ; Middle Aged ; Aged ; Japan/epidemiology ; Adult ; Aromatase Inhibitors/therapeutic use ; Aromatase Inhibitors/administration & dosage ; Aged, 80 and over ; East Asian People

المؤلفون: Meszár V; Research Directorate, Gedeon Richter Plc, Budapest, Hungary., Magyar G; Research Directorate, Gedeon Richter Plc, Budapest, Hungary., Pásztor GM; Research Directorate, Gedeon Richter Plc, Budapest, Hungary., Szatmári B; Research Directorate, Gedeon Richter Plc, Budapest, Hungary., Péter K; Research Directorate, Gedeon Richter Plc, Budapest, Hungary., Marton L; Research Directorate, Gedeon Richter Plc, Budapest, Hungary., Dombi ZB; Research Directorate, Gedeon Richter Plc, Budapest, Hungary., Barabássy Á; Research Directorate, Gedeon Richter Plc, Budapest, Hungary.

المصدر: Pharmacopsychiatry [Pharmacopsychiatry] 2024 Jul; Vol. 57 (4), pp. 180-185. Date of Electronic Publication: 2024 May 06.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I

بيانات الدورية: Publisher: Georg Thieme Verlag Country of Publication: Germany NLM ID: 8402938 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-0795 (Electronic) Linking ISSN: 01763679 NLM ISO Abbreviation: Pharmacopsychiatry Subsets: MEDLINE

مواضيع طبية MeSH: Cross-Over Studies* , Therapeutic Equivalency* , Tablets* , Antipsychotic Agents*/administration & dosage , Antipsychotic Agents*/pharmacokinetics , Piperazines*/administration & dosage , Piperazines*/pharmacokinetics, Humans ; Male ; Adult ; Young Adult ; Female ; Administration, Oral ; Middle Aged ; Area Under Curve ; Capsules

المؤلفون: Else LJ; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK., Dickinson L; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK., Edick S; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Zyhowski A; Magee-Womens Research Institute, Pittsburgh, PA, USA., Ho K; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Meyn L; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Dilly-Penchala S; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK., Thompson B; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK., Shaw V; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK., Khoo S; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK., Brand RM; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Magee-Womens Research Institute, Pittsburgh, PA, USA.

المصدر: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Jul 01; Vol. 79 (7), pp. 1597-1605.

نوع المنشور: Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE

مواضيع طبية MeSH: Pyridones*/urine , Oxazines* , Heterocyclic Compounds, 3-Ring*/pharmacokinetics , Heterocyclic Compounds, 3-Ring*/urine , Heterocyclic Compounds, 3-Ring*/blood , Heterocyclic Compounds, 3-Ring*/therapeutic use , Emtricitabine*/urine , Emtricitabine*/pharmacokinetics , Emtricitabine*/therapeutic use , Emtricitabine*/blood , Piperazines*/urine , Piperazines*/blood , Lamivudine*/urine , Lamivudine*/pharmacokinetics , Lamivudine*/blood , Point-of-Care Testing* , HIV Infections*/drug therapy , Tenofovir*/urine , Tenofovir*/pharmacokinetics , Tenofovir*/therapeutic use , Tenofovir*/blood , Anti-HIV Agents*/urine , Anti-HIV Agents*/pharmacokinetics , Anti-HIV Agents*/blood , Anti-HIV Agents*/therapeutic use, Humans ; Male ; Adult ; Female ; Middle Aged ; Pre-Exposure Prophylaxis/methods ; Young Adult ; Plasma/chemistry ; Medication Adherence

المؤلفون: Zhang Y; Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China., He X; Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China., Gu L; Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China., Li S; Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China., Tang J; Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China., Ma R; Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China., Yang H; Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address: yang_hx430@csu.edu.cn., Peng Z; Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008, China; Hunan Key Lab of Organ Fibrosis, Changsha 410008, China; National International Collaborative Research Center for Medical Metabolomics, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address: pengzhangzhe@csu.edu.cn.

المصدر: Biochemical pharmacology [Biochem Pharmacol] 2024 Jul; Vol. 225, pp. 116267. Date of Electronic Publication: 2024 May 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Liver Failure, Acute*/drug therapy , Liver Failure, Acute*/chemically induced , Liver Failure, Acute*/metabolism , Liver Failure, Acute*/pathology , MAP Kinase Kinase 4*/metabolism , MAP Kinase Kinase 4*/antagonists & inhibitors , Pyridones*/pharmacology , Pyridones*/therapeutic use , Piperazines*/pharmacology , Piperazines*/therapeutic use, Animals ; Male ; Mice ; Cell Line ; Galactosamine/toxicity ; Lipopolysaccharides/toxicity ; MAP Kinase Signaling System/drug effects ; MAP Kinase Signaling System/physiology ; Mice, Inbred C57BL ; Oxidative Stress/drug effects